THE WOODLANDS, Texas,
Sept. 13, 2011 /PRNewswire/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering breakthrough treatments for human
disease, reported positive data from a recently completed clinical
trial and mechanistic study of LX4211, a dual inhibitor of the
sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The
favorable safety profile and effects on multiple parameters of
glycemic control and cardiovascular health in healthy normal
subjects support the broad potential of LX4211 in the treatment of
diabetes and associated metabolic conditions.
"Newly observed in this study were the effects of LX4211, in
healthy volunteers, of decreasing postprandial glucose levels
without hypoglycemia and substantially reducing triglycerides,"
said Brian Zambrowicz, Ph.D., executive vice president and chief
scientific officer. "Notably, the magnitudes of the
reductions in triglycerides were similar to current standard of
care prescription and clinical-stage medicines. By contrast,
reported results of SGLT2-selective compounds have demonstrated
minimal or no reductions in postprandial glucose in healthy
subjects and minimal or no triglyceride decreases in either healthy
normal volunteers or patients with type 2 diabetes."
Results from the study demonstrated that the 400 mg solid oral
dose of LX4211 compared to placebo significantly reduced mean
changes from baseline in fasting plasma glucose (p=0.005) and
post-prandial glucose levels (p